Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum

Award Number: U01AI182179
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/22/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2029

Group Awards By:

View Award Description

A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum - Project Abstract - A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum The scientific premise of this CRC proposal rests upon our three decades of work defining the molecular architecture of the outer membrane (OM) of Treponema pallidum subsp. pallidum (TPA), coupled with our successes combining bioinformatics, biophysical techniques, and localization methods with live TPA to topologically characterize TPA outer membrane proteins (OMPs) and define the syphilis spirochete’s ‘OMPeome’--its repertoire of OMPs. The central hypothesis is that the principal targets for a syphilis vaccine reside within TPA’s repertoire of rare OMPs. The current application builds upon the work of the current CRC U19 grant awarded to the two mPIs of this proposal (Moody and Radolf). This proposal brings together the expertise in spirochetology (Univ. of Connecticut) and vaccine development (Duke Human Vaccine Institute) to develop vaccines targeting TPA OMPs. The overarching hypothesis is that vaccines targeting TPA OMPs will elicit antibodies that can recognize intact treponemes, provide protection in animal models, and be producible using Good Manufacturing Practices (GMP) at the scale needed to perform a phase 1 clinical trial. This CRC proposal will focus on two main aims: Aim 1) Selection of an ECL vaccinogen panel and production of ECL mAbs with functional activity, with subaim 1.1 of finalizing the ECL vaccinogen panel through robust preclinical animal studies (Univ. of Connecticut) and subaim 1.2 of producing ECL mAbs with functional activity (Duke Human Vaccine Institute), and Aim 2) Selection and optimization of an ECL vaccine platform, with subaim 2.1 of generating functional ECL-specific Abs using mRNA-LNP immunogens (Univ. of Pennsylvania), and subaim 2.2 of generating functional ECL-specific Abs using SpyVLPs (Univ. of Connecticut), to be compared in animal protection studies in subaim2.3. Successful completion of the aims of this CRC U01 proposal will provide the preclinical data needed for an IND submission to the FDA, complete the process development for GMP production, and will result in the full design of a GMP campaign strategy and a plan for toxicology testing.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $2,242,760 )
2026	2026	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Allergy and Infectious Diseases Research	000	3	4/2/2026	NON-COMPETING CONTINUATION	$2,242,760
														Subtotal = $2,242,760

Issue Date FY: 2025 ( Subtotal = $2,276,756 )
2025	2025	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Allergy and Infectious Diseases Research	001	2	4/16/2025	NON-COMPETING CONTINUATION	$2,276,756
2025	2024	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Allergy and Infectious Diseases Research	000	1	11/14/2024	NEW	$0
														Subtotal = $2,276,756

Issue Date FY: 2024 ( Subtotal = $2,387,026 )
2024	2024	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Allergy and Infectious Diseases Research	000	1	4/22/2024	NEW	$2,387,026
														Subtotal = $2,387,026

Grand Total All Awards = $6,906,542

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum

Award Number: U01AI182179

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/22/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer